Trial Profile
A Long-term, Single-arm, Open-label Trial of NPC-12G (Topical Formulation of Sirolimus) to Angiofibroma and Other Skin Lesions in Patients With Tuberous Sclerosis Complex
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 May 2020
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Fibroma
- Focus Adverse reactions; Registrational
- Sponsors Nobelpharma
- 18 Feb 2019 Status changed from not yet recruiting to completed.
- 22 Dec 2015 New trial record